supported by the Ningxia Reproductive Disease Clinical Medical Research Center Project(No.2023LCYX003);Ningxia Hui Autonomous Region Natural Science Foundation Project(2022AAC03748);Ningxia Hui Autonomous Region Natural Science Foundation Project(No.2021AAC03523);Basic research project of Yinchuan Maternal and Child Health Hospital(No.2022NYFYCX05);Yinchuan Science and Technology Innovation Project(No.2023SF25);Basic research project of Yinchuan Maternal and Child Health Hospital(No.2023NYFYCX01)(all China).
Breast cancer(BRCA)is the dominating form of cancer affecting women,with an estimated 2.3 million newly diagnosed cases and 685,000 deaths in 2020.1 An emerging study has proposed a novel metabolism-related regulated ...
Although olaparib has demonstrated substantial clinical benefits as maintenance therapy in BRCA mutation-carrying women with newly diagnosed advanced ovarian cancer,its effectiveness in patients without BRCA mutations...
supported by the National Natural Science Foundation of China(grant number:82303223);the Basic and Applied Basic Research Foundation of Guangdong Province(grant numbers:2021A1515220064,2022A1515110299);the Medical Scientific Re-search Foundation of Guangdong Province(grant number:A2022492).
Background:The homologous recombination deficiency(HRD)score serves as a promising biomarker to iden-tify patients who are eligible for treatment with PARP inhibitors(PARPi).Previous studies have suggested a 3-biomark...
根据国际癌症研究机构(International Agency for Research on Cancer, IARC)与WHO GLOBOCAN的最新报告,截至2018年,全球范围内女性乳腺癌新增病例已超过200万,标准化发病率攀升至每十万名女性中46.3例。2022年中国国家癌症中心数据显示...
BACKGROUND Poly(ADP-ribose)polymerase inhibitors(PARPis)are approved as first-line therapies for breast cancer gene(BRCA)-positive,human epidermal growth factor receptor 2-negative locally advanced or metastatic breas...